WO2003068921A3 - Therapeutic polypeptides, nucleic acids encoding same, and methods of use - Google Patents

Therapeutic polypeptides, nucleic acids encoding same, and methods of use Download PDF

Info

Publication number
WO2003068921A3
WO2003068921A3 PCT/US2003/004188 US0304188W WO03068921A3 WO 2003068921 A3 WO2003068921 A3 WO 2003068921A3 US 0304188 W US0304188 W US 0304188W WO 03068921 A3 WO03068921 A3 WO 03068921A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nucleic acids
acids encoding
encoding same
therapeutic polypeptides
Prior art date
Application number
PCT/US2003/004188
Other languages
French (fr)
Other versions
WO2003068921A2 (en
Inventor
Luca Rastelli
Haihong Zhong
Ferenc L Boldog
Esha A Gangolli
Xiaojia Guo
Uriel M Malyankar
Meera Patturajan
Carol E A Pena
Richard A Shimkets
Kimberley A Spytek
Corine A M Vernet
Daniel K Rieger
Shlomit R Edinger
Catherine E Burgess
Original Assignee
Curagen Corp
Luca Rastelli
Haihong Zhong
Ferenc L Boldog
Esha A Gangolli
Xiaojia Guo
Uriel M Malyankar
Meera Patturajan
Carol E A Pena
Richard A Shimkets
Kimberley A Spytek
Corine A M Vernet
Daniel K Rieger
Shlomit R Edinger
Catherine E Burgess
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Luca Rastelli, Haihong Zhong, Ferenc L Boldog, Esha A Gangolli, Xiaojia Guo, Uriel M Malyankar, Meera Patturajan, Carol E A Pena, Richard A Shimkets, Kimberley A Spytek, Corine A M Vernet, Daniel K Rieger, Shlomit R Edinger, Catherine E Burgess filed Critical Curagen Corp
Priority to AU2003219743A priority Critical patent/AU2003219743A1/en
Publication of WO2003068921A2 publication Critical patent/WO2003068921A2/en
Publication of WO2003068921A3 publication Critical patent/WO2003068921A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to novel polypeptides, and the nucleic acids encoding them, having properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions.
PCT/US2003/004188 2002-02-12 2003-02-12 Therapeutic polypeptides, nucleic acids encoding same, and methods of use WO2003068921A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003219743A AU2003219743A1 (en) 2002-02-12 2003-02-12 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35637502P 2002-02-12 2002-02-12
US60/356,375 2002-02-12
US38708202P 2002-06-07 2002-06-07
US60/387,082 2002-06-07

Publications (2)

Publication Number Publication Date
WO2003068921A2 WO2003068921A2 (en) 2003-08-21
WO2003068921A3 true WO2003068921A3 (en) 2004-04-08

Family

ID=27737531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004188 WO2003068921A2 (en) 2002-02-12 2003-02-12 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Country Status (2)

Country Link
AU (1) AU2003219743A1 (en)
WO (1) WO2003068921A2 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUGUET E.L. ET AL.: "Differential expression of human Wnt genes 2, 3, 4 and 7B in human breast cell lines and normal and disease states of human breast tissue", CANCER RES., vol. 54, no. 10, 15 May 1994 (1994-05-15), pages 2615 - 2621, XP002121611 *

Also Published As

Publication number Publication date
AU2003219743A1 (en) 2003-09-04
WO2003068921A2 (en) 2003-08-21
AU2003219743A8 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
WO2003031572A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2005078097A3 (en) RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (Multifunctional siNA)
HUP0500054A2 (en) Method for identification of tumor targeting enzymes
WO1997045541A3 (en) Patched genes and their uses
WO2001038503A3 (en) Novel human protein kinases and protein kinase-like enzymes
WO1995025171A3 (en) Dna sequences for matrix metalloproteases, their production and use
WO2003076578A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003029429A3 (en) Traversal of nucleic acid molecules through a fluid space and expression in repair cells
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
WO2004018633A3 (en) Abca13 nucleic acids and proteins, and uses thereof
HRP20020093A2 (en) Polymorphisms in the human mdr-1 gene and their use in diagnostic and therapeutic applications
WO2000008157A3 (en) Human anion transporter genes atnov
WO2003068921A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2005110460A3 (en) Diagnosis and treatment methods related to aging, especially in muscle (14.1)
CY1110911T1 (en) Human TSC403 gene
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
WO2001049879A3 (en) Methods for comparing gene expression levels or patterns in normal or tumor cells
EP1494031A3 (en) Novel human genes and gene expression products
WO2000058464A3 (en) Rab genes and their uses
WO2005014804A3 (en) Ubiquitin-specific protease
WO2004020582A3 (en) Mammalian genes involved in rapamycin resistance and tumorgenesis: rapr6 genes
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2003059148A3 (en) Gene expression profiles in stomach cancer
WO2003066877A3 (en) Compositions and methods relating to hepatic specific genes and proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP